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progression, signal transduction and transcription [7] . Cul1 plays a key role as a rigid scaffold in SCF complex assembly, and aberrant expression of Cul1 is involved in dysfunction of SCF E3 ligases [8] .
It has been reported that loss of Cul1 results in early embryonic lethality and deregulation of cyclin E [9] . Cul1 expression is increased in early stages of melanoma and increased Cul1 expression promotes melanoma cell proliferation through regulating p27 expression [10, 11] . In addition, Min et al. reported that Cul1 expression was correlated with histological grade, negative ER and positive HER2, and also shows a significant association with poor overall survival in breast cancer [12] . Previously, we have shown that overexpression of Cul1 is associated with poor prognosis of patients with gastric cancer [13] . In this study, we further investigated the role of Cul1 in the development of human breast cancer.
To evaluate the function of Cul1 in breast cancer, we used a tissue microarray (TMA) of human breast cancer patients and immunohistochemistry to analyze the correlation between Cul1 expression and clinicopathologic variables and patient survival. In addition, we further investigated the role of Cul1 in breast cancer cell proliferation, migration and invasion.
materials and methods

patient specimens
The study material consists of a series of 393 consecutive cases of primary invasive breast carcinoma, from The First Affiliated Hospital of Nanjing Medical University, between 1996 and 2005. All these patients were treated with surgery only or with postoperative adjuvant therapy. The patients' clinicopathologic information was obtained from the archive of the pathology department and confirmed by the medical record of the hospital. The histologic grade was assessed using Bloom-Richardson classification. Five-year clinical follow-up results were available for 224 patients. The use of these specimens and data for research purposes was approved by the Ethics Committee of the Hospital.
immunohistochemistry of TMA
Immunohistochemistry was carried out according to the avidin biotinalated-HRP complex method. Briefly, sections were deparaffinized, rehydrated and retrieved in water bath, using citrate buffer for 20 min. The TMA slides were incubated with a monoclonal mouse anti-Cul1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C overnight, and diaminobenzidine (Zhongshan Biotech, Beijing, China) was used to produce a brown precipitate. Negative controls were obtained by substituting primary antibodies with non-immune serum.
evaluation of immunostaining
The evaluation of Cul1 staining was blindly and independently examined by two pathologists. Positive Cul1 immunostaining is defined as cytoplasmic with or without nuclear staining and graded according to both the intensity and percentage of cells with positive staining. The Cul1 staining intensity was scored 0-3 (0 = negative; 1 = weak; 2 = moderate; 3 = strong). The percentage of Cul1-positive stained cells was also scored into four categories: 1 (0%-25%), 2 (26%-50%), 3 (51%-75%) and 4 (76%-100%). The level of Cul1 staining was evaluated by the immunoreactive score (IRS), which is calculated by multiplying the scores of staining intensity and the percentage of positive cells. Based on the IRS, the Cul1 staining pattern was defined as negative (IRS: 0), weak (IRS: 1-2), moderate (IRS: 3-6) and strong (IRS: 8-12).
cell culture and transfection
Two human breast carcinoma cell lines MDA-MB-231 and BT-549 were purchased from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). Cells were cultured in RPMI 1640 medium and supplemented with 10% fetal bovine serum (Invitrogen, Shanghai, China). Cells were grown to 50% confluence before small-interfering RNA (siRNA) transfection. Nonspecific control siRNA (Qiagen, Mississauga, ON, Canada) or Cul1 siRNA (Dharmacon, Lafayette, CO) was transfected by siLentFect Lipid Reagent (Bio-Rad, Hercules, CA) according to the manufacturer's instructions.
western blot analysis
Western blots were carried out as previously described [14] . The following antibodies were used for western blot: mouse anti-Cul1 (Santa Cruz Biotechnology), mouse anti-cyclin A, anti-cyclin E, anti-p21, anti-p27, rabbit anti-cyclin D1, anti-MMP-2, anti-TIMP-2 (all from Cell Signaling Technology, Beverly, MA) and mouse anti-β-actin (Boster Biotechnology, Wuhan, China).
cell proliferation assay
Cellular proliferation was analyzed using a WST-8 cell counting kit-8 (Beyotime, Nantong, China). 3 × 10 3 cells were seeded in 96-well plates and incubated for 24 h, 48 h, 72 h and 96 h. Ten microliter CCK-8 solution was added to each well and the cultures were incubated at 37°C for 1 h. Absorbance at 450 nm was measured using an ELX-800 spectrometer reader (Bio-Tek Instruments, Winooski).
cell-cycle analysis
Thirty-six hours after transfection, the cells were treated with 1 μg/ml aphidicolin. After 12 h, the cells were incubated in fresh medium containing 50 ng/ml nocodazole for 0, 3 or 6 h. Then, the cells were fixed with 70% cold ethanol at 4°C overnight, and stained with 40 μg/ml propidium iodide in hypotonic fluorochrome buffer for 30 min. Samples were then analyzed using a FACSCanto flow cytometer (BD Biosciences, San Jose, CA).
migration assay
Cell migration was determined by using a modified two-chamber migration assay with a pore size of 8 μm. 1 × 10 5 cells were seeded in serum-free medium in the upper chamber. After 12 h incubation at 37°C, cells in the upper chamber were carefully removed with a cotton swab and the cells that had traversed the membrane were fixed in methanol, stained with Trypan Blue and counted.
invasion assay
The invasion assay was carried out using a modified two-chamber plates with a pore size of 8 μm. The transwell filter inserts were coated with matrigel. 2 × 10 5 cells were seeded in serum-free medium in the upper chamber. After 24 h incubation at 37°C, the cells in the upper chamber were carefully removed with a cotton swab and the cells that had traversed the membrane were fixed in methanol, stained with Trypan Blue and counted. Figure 2A ). Interestingly, we also found that increased Cul1 expression is significantly correlated with negative ER (P = 0.001, χ 2 test, Figure 2B ), negative PR (P = 0.001, χ 2 test, Figure 2C ) and positive HER2 (P = 0.002, Figure 2D ). We did not find any significant correlations between Cul1 expression and other clinicopathologic variables, including patient age, tumor size, lymph node metastasis and histology type.
increased Cul1 expression with poor patient survival
We then analyzed whether Cul1 expression was associated with the survival of patients by Kaplan-Meier survival analysis. Our data revealed that positive Cul1 staining correlated with both 5-year overall and disease-specific patient survival (P = 0.026 and P = 0.015, respectively, log-rank test; Figure 2E and F). The univariate Cox regression analyses revealed that Cul1 expression was significantly associated with overall or diseasespecific survival in breast cancer patients (P = 0.029 and P = 0.018, respectively, supplementary Table S1, available at Annals of Oncology online). In supplementary Table S2 , available at Annals of Oncology online, the multivariate Cox regression model indicated that expression of Cul1 is an independent prognostic marker for both overall and diseasespecific survival (P = 0.025 and P = 0.016, respectively).
Cul1 regulates cell proliferation in breast cancer cells
Small-interfering RNA was used to knock down Cul1 expression in both MDA-MB-231 and BT-549 cells for an in vitro study ( Figure 3A) . In a CCK-8 cell proliferation assay, we found that the ability of cell proliferation was drastically decreased after Cul1 knockdown in both cell lines ( Figure 3B ). We then examined whether knockdown of Cul1 induced inhibition of breast cancer cell growth is due to cell-cycle arrest using fluorescence activate cell sorting. Our data showed that Cul1 knockdown cells have significantly higher G1 population than control cells in both the cell lines ( Figure 3C ). Western blot results showed that the mechanism of Cul1 regulation on cell-cycle progression is due to increased expression of p21 and p27, and decreased expression of cyclin A, cyclin D1 and cyclin E after Cul1 knockdown ( Figure 3D ). 
silencing of Cul1 inhibits breast cancer cells migration and invasion in vitro
We next investigated the role of Cul1 in migration and invasion of breast cancer cells by a migration assay and matrigel invasion assay. In a cell migration assay, our data showed that Cul1 knockdown decreased cells migration ability of MDA-MB-231 and BT-549 cells by 83% and 77%, respectively ( Figure 4A ). In a cell invasion assay, silencing of Cul1 inhibited cell invasive ability of MDA-MB-231 and BT-549 cells by 84% and 79%, respectively ( Figure 4B ). Gelatin zymography data revealed that MMP-2 enzyme activity was significantly suppressed after knockdown of Cul1 in MDA-MB-231 and BT-549 cells ( Figure 4C ). Western blot results showed that the inhibition of the MMP-2 protein level is due to the increased expression of TIMP-2 after Cul1 knockdown in both cell lines ( Figure 4D ).
discussion
Histological grade, ER, PR and HER2 status all influence breast cancer prognosis and probability of response to systemic therapies [15] . Endocrine therapy is probably the most important systemic therapy for hormone receptor-positive breast cancer [16] . The loss of ER expression is thought to be involved in endocrine therapy resistance. Investigation surrounding the ER-negative phenotype has suggested that hyperactivation of the mitogen-activated protein kinase (MAPK) pathway reversibly inhibits the expression of the ER [17] . Although its role in breast cancer has not been addressed, it is possible that overexpression of Cul1 may contribute to a hyperactivated MAPK pathway in breast cancer. Patients with a HER2-positive breast cancer diagnosis often experience more aggressive tumor progression and an inferior prognosis [18] . Our studies showed a significant correlation between Cul1 and HER2. But interactions between Cul1 and HER2 signaling pathways remain poorly characterized. Cyclins, their associated kinases (CDKs), and cyclininhibitory proteins are integral components in the coordinated progression of the cell cycle. We found that the ability of cell proliferation was drastically decreased after Cul1 knockdown in breast cancer cells by an arrest in the cell-cycle progression at the G1 to S transition. Cyclin A-CDK2, cyclin D1-CDK2 and cyclin E-CDK2 complex operates at the G1 to S transition [19] . 
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Cyclin/CDK complexes are precisely regulated by Cip/Kip proteins, such as p21 and p27, which can bind and inhibit CDK activity at the G1/S cell-cycle checkpoint [20] . Our data showed that knockdown of Cul1 simultaneously up-regulated p27 and p21 expression, which subsequently inhibits the expression of cyclin A, cyclin D1 and cyclin E. However, it remains to be elucidated how Cul1 regulates p27 and p21 expression in breast cancer cell proliferation. 
